Table 1.
Patients Demographics.
| Categories | Incidence/Value |
|---|---|
| Age (years) | 61.3 ± 12.4 (27–85) |
| Gender | |
| Female | 22 (34.3%) |
| Male | 42 (65.6%) |
| Etiology of liver disease | |
| HBV | 37 (57.8%) |
| HCV | 9 (14.1%) |
| Multifactorial/ others | 18 (28.1%) |
| Child-Pugh class | |
| A | 44 (68.7%) |
| B | 20 (31.3%) |
| Underlying disease | |
| Diabetes | 25 (39.1%) |
| Hypertension | 15 (23.4%) |
| Renal function impairment | 6 (9.3%) |
| Tumor burden | |
| >50% | 14 (21.9%) |
| <50% | 50 (78.1%) |
| Frequencies of DEM-TACE treatments | 2.17 (1–5) |
| Pre-DEM-TACE AFP level | |
| <20 | 25 (39.1%) |
| >20 | 39 (60.9%) |
| Size of target lesion (cm) before DEM-TACE | 6.7 ± 4.0 (1.2–20.3) |
| Sorafenib usage | 18 (28.1%) |
| Intrahepatic vein invasion (n = 42) | 42 (65.6%) |
| Portal vein | 32/42 (76.2%) |
| Systemic vein | 3/42 (7.1%) |
| Both | 7/42 (16.7%) |
| Extrahepatic Spread | 10 (15.6%) |
| ECOG | |
| 0 | 52 (81.3%) |
| 1–2 | 12 (18.7%) |
Data are expressed as mean standard deviation for continuous variables. Other data are expressed as number of patients(percentage) for categorical variables. HBV: Hepatitis B virus; HCV: Hepatitis C virus; DEM-TACE: Drug-eluting transarterial chemoembolization; BCLC: Barcelona Clinic Liver Cancer; ECOG: Eastern Cooperative Oncology Group.